Drug Information

Drug General Information
Drug ID
D0G1YA
Former ID
DNCL001941
Drug Name
PF-05212377
Synonyms
SAM-760
Indication Alzheimer disease [ICD9: 331; ICD10:G30] Phase 2 [524103]
Company
Pfizer New York, NY
Target and Pathway
Target(s) 5-hydroxytryptamine 6 receptor Target Info Antagonist [550237]
KEGG Pathway Calcium signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Serotonergic synapse
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
PathWhiz Pathway Excitatory Neural Signalling Through 5-HTR 6 and Serotonin
Reactome Serotonin receptors
G alpha (s) signalling events
WikiPathways Serotonin Receptor 4/6/7 and NR3C Signaling
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signaling
References
Ref 524103ClinicalTrials.gov (NCT01712074) Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil. U.S. National Institutes of Health.
Ref 550237PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.